Clinical Trial: Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905210) titled 'Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris' on March 25.

Brief Summary: This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six 28-day treatment cycles. Eligible participants will be randomized (2:1) to receive either the experimental drug or placebo alongside standard skincare. The study includes five in-person visits (screening, randomization, and thr...